421 related articles for article (PubMed ID: 19369008)
1. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
2. [Isolation and characterization of brain tumor stem cells in human medulloblastoma].
Li MC; Deng YW; Wu J; Chen FH; Liu JF; Fang JS
Ai Zheng; 2006 Feb; 25(2):241-6. PubMed ID: 16480595
[TBL] [Abstract][Full Text] [Related]
3. [Correlation research between cancer stem cells and the pathological grades of neuroepithelial tumors].
Deng YW; Fang JS; Li MC; Chen FH; Zhou XY; Wu J; Zhou RH; Fang F; Chen C; Lu M; Zeng FY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):45-51. PubMed ID: 16562674
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells in the central nervous system--a critical review.
Prestegarden L; Enger PØ
Cancer Res; 2010 Nov; 70(21):8255-8. PubMed ID: 20959482
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
7. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
[TBL] [Abstract][Full Text] [Related]
8. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
9. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
11. Limits of CD133 as a marker of glioma self-renewing cells.
Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
[TBL] [Abstract][Full Text] [Related]
12. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
13. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
14. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
15. Research progression of CD133 as a marker of cancer stem cells.
Zhang H; Li SY
Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
[TBL] [Abstract][Full Text] [Related]
16. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
17. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
20. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
